HONG KONG – Following the National Development and Reform Commission (NDRC)’s notice on removing the government price cap on most of the drugs in China, the government is slowly but gradually loosening its grip on drug prices. Large domestic pharmaceutical firms are most likely to benefit from that deregulation. Read More

TOKYO – Japan’s National Cancer Center (NCC) and pharma major Takeda Pharmaceutical Co. Ltd. have joined forces to discover and develop cancer drugs in Japan and ensure their quick delivery to patients. Read More

Celltrion Inc., of Incheon, South Korea, reported clinical experience of its biosimilar infliximab in 78 inflammatory bowel disease patients at Digestive Disease Week in Washington, showing that treatment is comparable to the reference product, Remicade (Johnson & Johnson), in terms of efficacy and safety. Read More

SHANGHAI – The CFDA has an unenviable task on its hands. The agency has an enormous workload supporting the world’s second-largest drug market, made more complex given it is still in a developing phase. Regulators not only have to keep up with up an 18 percent year-on-year increase in drug applications that require their review and assessment, they are simultaneously trying to construct the legal architecture necessary to regulate the industry overall. Read More

HONG KONG – After eyeing biopharmaceuticals as a key area for breakthrough developments, China’s State Council has released a roadmap for the manufacturing sector. Read More

HONG KONG – Not only is China’s biotech sector growing fast, but it is also changing rapidly. And those changes in its basic structure are appealing to Asia-focused biotech investors who gathered this week at Asia Biotech Invest 2015. Read More